Verve Therapeutics Earnings Estimate

By analyzing Verve Therapeutics' earnings estimates, investors can diagnose different trends across Verve Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Verve Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Verve Therapeutics is projected to generate -0.61155 in earnings per share on the 31st of December 2024. Verve Therapeutics earnings estimates module stress-tests analyst consensus about projected Verve Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Verve Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Verve Therapeutics' earnings estimates, investors can diagnose different trends across Verve Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to climb to about (164.5 M) in 2024. Pretax Profit Margin is likely to drop to -17.84 in 2024Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verve Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.